Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4507 On Other Exchanges
Symbol
Exchange
4507 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

shionogi & co ltd (4507) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHIONOGI & CO LTD (4507)

Related News

No related news articles were found.

shionogi & co ltd (4507) Related Businessweek News

No Related Businessweek News Found

shionogi & co ltd (4507) Details

Shionogi & Co., Ltd. manufactures and distributes pharmaceuticals, diagnostic reagents, medical devices, etc. primarily in Asia, North America, and Europe. Its principal products include various prescription drugs, including Osphena to treat postmenopausal vulvar and vaginal atrophy; Crestor tablets for the treatment of hyperlipidemia; Irbetan tablets for the treatment of hypertension; Cymbalta capsules to treat depression, depressive condition, and diabetic neuropathic pain; cancer pain analgesics, such as OxyContin tablets, OxiNorm powders, and OxiFast injections; Tivicay tablets for HIV treatment; Finibax and Finibax solution kit for intravenous drip infusion; Differin gel for the treatment of topical acne vulgaris; Pirespa tablets used to treat idiopathic pulmonary fibrosis; and Rapiacta, an antiviral drug for the treatment of influenza. The company also offers over the counter drugs comprising Popon series of multiple vitamin supplements; and Sedes, a line of analgesic antipyretics. In addition, it provides diagnostics reagents, such as Shionospot Reader and Shionospot BNP, a human brain natriuretic peptide kit; Allerport TARC, a thymus and activation-regulated chemokine kit; Allerport HRT, a reagent for identifying allergens; Brightpoc Flu, an influenza virus diagnostic kit; and Checkart Reader for measuring hemoglobin A1c and glucose levels in blood for use in diagnosing diabetes and other related clinical conditions. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

6,059 Employees
Last Reported Date: 05/11/15
Founded in 1878

shionogi & co ltd (4507) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

shionogi & co ltd (4507) Key Developments

Shionogi & Co., Ltd. Reports Consolidated and Non-Consolidated Financial Results for the Full Year Ended March 31, 2015; Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2016; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2015; Announces Dividend for the Fiscal Year Ended March 31, 2015, Payable on June 25, 2015; Provides Dividend Guidance for the Fiscal Second Quarter and Full Year Ending March 31, 2016

Shionogi & Co., Ltd. reported consolidated and non-consolidated financial results for the full year ended March 31, 2015. For the year, on consolidated basis, the company reported net sales of JPY 289,717 million against JPY 289,717 million a year ago. Operating income was JPY 50,365 million against JPY 61,875 million a year ago. Ordinary income was JPY 77,880 million against JPY 62,225 million a year ago. Income before income taxes and minority interests was JPY 82,051 million against JPY 63,188 million a year ago. Net income was JPY 44,060 million or JPY 132.04 per diluted share against JPY 40,618 million or JPY 121.23 per diluted share a year ago. Return on equity was 9.2% compared to 9.4% last year. Net assets per share were JPY 1,456.70 compared to JPY 1,385.11 per share last year. Cash flows from operating activities were JPY 45,604 million compared to JPY 79,496 million last year. Purchase of property, plant and equipment was JPY 10,640 million compared to JPY 6,960 million last year. Net income was down 37.3% was due to about JPY 30 billion of decrease in taxes on an unconsolidated basis related to an impairment loss at Shionogi Inc. associated with transactions of ViiV in the last fiscal year. For the year, on non-consolidated basis, the company reported net sales of JPY 246,980 million against JPY 259,760 million a year ago. Operating income was JPY 61,398 million against JPY 71,525 million a year ago. Ordinary income was JPY 70,409 million against JPY 73,530 million a year ago. Net income was JPY 42,153 million or JPY 126.33 per diluted share against net loss of JPY 54,600 million or JPY 162.96 per share a year ago. Net assets per share were JPY 1,304.97 compared to JPY 1,153.74 per share last year. For the full year ending March 31, 2016, on consolidated basis, the company expects net sales of JPY 296,000 million, operating income of JPY 72,500 million, ordinary income of JPY 79,500 million and net income of JPY 52,000 million or JPY 159.72 per share. For the six months ending September 30, 2015, on consolidated basis, the company expects net sales of JPY 138,000 million, operating income of JPY 28,500 million, ordinary income of JPY 28,000 million and net income of JPY 17,000 million or JPY 52.22 per share. For the full year ended March 31, 2015, the company declared year end dividend of JPY 28.00 per share and annual dividend of JPY 52.00 per share. The scheduled date of dividend payments will be June 26, 2014. For the full year ending March 31, 2016, the company expects to pay year end dividend of JPY 28.00 per share and annual dividend of JPY 56.00 per share compared to declared dividends for the year end of JPY 28.00 per share and annual dividend of JPY 52.00 per share last year. For the second quarter ending September 30, 2015, the company expects to pay dividend of JPY 28.00 per share compared to declared dividend of JPY 24.00 per share last year.

Shionogi & Co., Ltd. to Report Fiscal Year 2015 Results on May 11, 2015

Shionogi & Co., Ltd. announced that they will report fiscal year 2015 results on May 11, 2015

Shionogi & Co., Ltd., 2015 Earnings Call, May 12, 2015

Shionogi & Co., Ltd., 2015 Earnings Call, May 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4507:JP ¥4,610.00 JPY +35.00

4507 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.34 USD +0.20
Pfizer Inc $34.36 USD +0.06
Theravance Inc $16.31 USD +0.07
View Industry Companies
 

Industry Analysis

4507

Industry Average

Valuation 4507 Industry Range
Price/Earnings 34.3x
Price/Sales 5.4x
Price/Book 3.1x
Price/Cash Flow 36.1x
TEV/Sales 5.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIONOGI & CO LTD, please visit www.shionogi.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.